'Biotech has certainly been a beneficiary of that trade': Maneulian on biotech small cap rebound

Key Concepts

• Biotech M&A (Mergers and Acquisitions): The consolidation of smaller biotech firms by large-cap pharmaceutical companies to bolster pipelines.
• Commercial-Stage Biopharma: Companies that have moved beyond research and development to having at least one FDA-approved product generating revenue.
• PDUFA Date: The Prescription Drug User Fee Act date; the deadline by which the FDA must respond to a New Drug Application (NDA) or Biologics License Application (BLA).
• Phase 2/3 Clinical Trials: Mid-to-late stage testing to determine efficacy and safety in larger patient populations.
• Market Rotation: The shifting of capital from value stocks into growth and momentum-oriented sectors, such as mid-cap biotech.

---

Current State of the Biotech Sector

Sahak Manuelian, Managing Director at Wedbush, characterizes the current biotech landscape as highly active, driven by a robust M&A environment.

• Market Dynamics: Since mid-2025, the sector has benefited from a rotation into growth stocks. Previously, small-cap biotech suffered from low positioning and negative sentiment, but the sector has since experienced a significant rebound.
• M&A Activity: Large-cap pharma companies are aggressively seeking "under-the-radar" therapeutics companies to fill pipeline gaps. A notable example cited is the ~$11 billion acquisition of Apogee by AbbVie.

---

Top Biotech Picks

1. Kiniksa Pharmaceuticals (KNSA)

• Profile: A commercial-stage company focused on auto-inflammatory cardiovascular diseases.
• Key Product: Arcalyst (Rilonacept), approved for recurrent pericarditis (RP).
• Financial Performance: Reported Q1 revenue of $214 million, representing a 6% quarter-over-quarter increase and a 56% year-over-year growth. The company has raised its full-year guidance.
• Growth Catalyst: The pipeline candidate KPL-387 is in Phase 2/3 trials. If approved, it offers a competitive advantage with once-a-month dosing (compared to the current weekly dosing of Arcalyst) and, crucially, 100% revenue retention for Kiniksa, as it lacks the revenue-sharing agreement currently in place with Regeneron for Arcalyst.

2. Monte Rosa Therapeutics (GLUE)

• Profile: A small-cap firm focused on oncology and inflammatory/immune diseases.
• Therapeutic Areas: Prostate cancer, rheumatoid arthritis, ulcerative colitis (UC), and Hidradenitis Suppurativa (HS).
• Upcoming Milestones:
  • Q3 2026: Phase 2 update for their prostate cancer program.
  • Q4 2026: Initiation of Phase 2 trials for MRT 8102 in gout flares.
  • Q1 2027: Planned initiation of trials for HS, a severe skin disease.

3. Scholar Rock (SRRK)

• Profile: Focused on spinal muscular atrophy (SMA).
• Key Catalyst: The company has a PDUFA date set for September 30th.
• Investment Thesis: Manuelian expresses high confidence in FDA approval based on positive Phase 3 data, which showed significant improvements in motor function and a strong safety profile.
• Financial Outlook: Revenue estimates are projected at $163 million for 2027, scaling to $450 million by 2028. Beyond standalone growth, the company is viewed as a prime M&A target for large-cap firms looking to acquire SMA-related assets.

---

Synthesis and Conclusion

The biotech sector is currently experiencing a "tailwind" driven by a shift toward growth stocks and a high appetite for M&A among large-cap pharmaceutical companies. The investment strategy presented focuses on three distinct stages of development:

1. Kiniksa: Leveraging an existing commercial success to transition into a higher-margin, proprietary pipeline.
2. Monte Rosa: A long-term play on a diverse, early-to-mid-stage pipeline targeting high-need inflammatory and oncological conditions.
3. Scholar Rock: A near-term catalyst play centered on an upcoming FDA regulatory decision and potential acquisition interest.

Manuelian’s outlook suggests that for investors, the primary value lies in identifying companies with strong clinical data that can either scale independently or serve as strategic acquisition targets for larger industry players.